NVIC Articles

Meningitis

Disease-Vaccine-Landing-Page/Meningitis

Latest articles

Browse Articles

Placeholder image
Page

Contraindications to receiving PENBRAYA meningococcal vaccine include a history of severe allergic reaction to any of the ingredients found within the vaccine. The PENBRAYA vaccine package insert also warns that persons...

Placeholder image
Page

Contraindications to receiving BEXSERO meningococcal group B vaccine documented in Novartis Vaccines and Diagnostics (GlaxoSmithKline) package insert include: Individuals who experienced hypersensitivity or a severe allergic reaction after a previous dose...

Placeholder image
Page

Contraindications to receiving Menveo meningococcal (Groups A, C, Y, and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine documented in Novartis Vaccines and Diagnostics (GlaxoSmithKline) package insert include: Individuals who experienced a severe...

Placeholder image
Page

In addition to reactions and injuries following meningococcal vaccination, administration errors resulting in adverse events have also been reported. Menactra (MCV4/MenACWY-D) meningococcal conjugate vaccine is approved to be administered intramuscularly...

Placeholder image
Page

As of December 27, 2024, there have been 49,696 reports of meningococcal vaccine reactions, hospitalizations, injuries and deaths following meningococcal vaccinations made to the federal Vaccine Adverse Events Reporting System...

Placeholder image
Page

In clinical trials of Pfizer’s PENBRAYA pentavalent meningococcal vaccine, trial participants received either a dose of PENBRAYA meningococcal vaccine (MenABCWY) or meningococcal (serogroups A, C, W and Y) oligosaccharide diphtheria...

Placeholder image
Page

According to the CDC, more than 50 percent of meningococcal serogroup B (BEXSERO or TRUMENBA) vaccine recipients experience mild side effects that may include pain, redness, and swelling to the...

Placeholder image
Page

According to the CDC, individuals receiving meningococcal vaccines targeting meningococcal serogroups A, C, Y, and W-135 (Menactra or Menveo) may experience mild side effects such as pain or redness at...

Placeholder image
Page

In October 2023, the FDA approved use of PENBRAYA, a pentavalent meningococcal vaccine targeting the A, B, C, W, and Y meningococcal serogroups. According to the vaccine’s package insert, the...

Placeholder image
Page

Meningococcal serogroup B (MenB) vaccines received FDA approval based on blood tests indicating immune response (immunogenicity) to the particular strains found within the vaccine. Meningococcal serogroup B strains, however, are...

Topics
Select disease / vaccine